Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

被引：0
|
作者：
Patnaik, Amita
Socinski, Mark A.
Gubens, Matthew A.
Gandhi, Leena
Stevenson, James
Bachman, Robert D.
Bourque, Jennifer
Ge, Joy Yang
Im, Ellie
Gadgeel, Shirish M.
机构：
[1] START, San Antonio, TX USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] UC San Francisco, San Francisco, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase 3 ZEAL-1L study
    Nagrial, Adnan
    Ramalingam, Suresh S.
    de Castro, Gilberto, Jr.
    Garassino, Marina Chiara
    Mazieres, Julien
    Sanborn, Rachel
    Smit, Egbert
    Spigel, David R.
    Thomas, Michael
    Velcheti, Vamsidhar
    Shi, Lei
    Neibauer, Melissa Whipple
    Stojadinovic, Alexander
    Peters, Solange
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 204 - 205
  • [32] Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC)
    Leighl, N
    Laurie, S
    Knox, J
    Ellis, P
    Shepherd, F
    Burkes, R
    Pond, G
    Zwiebel, J
    Moore, M
    LUNG CANCER, 2005, 49 : S256 - S256
  • [33] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
    Ramalingam, S. S.
    de Castro, G., Jr.
    Garassino, M. C. C.
    Mazieres, J.
    Sanborn, R. E.
    Smit, E. F. F.
    Spigel, D. R.
    Thomas, M.
    Velcheti, V.
    Zhi, E.
    Whipple Neibauer, M.
    Stojadinovic, A.
    Peters, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
  • [34] Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
    Reckamp, Karen L.
    CANCER LETTERS, 2012, 321 (02) : 101 - 109
  • [35] Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
    Govindan, R.
    Zergebel, C.
    Saito, K.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Niraparib (Nira) plus Pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
    Schuler, M.
    Ramalingam, S.
    Arora, S.
    Neibauer, Whipple M.
    Zho, J.
    Hazard, S.
    Frenkl, T.
    Stojadinovic, A.
    Peters, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 170 - 171
  • [37] Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
    Ceresoli, GL
    Gregorc, V
    Cordio, S
    Bencardino, KB
    Schipani, S
    Cozzarini, C
    Bordonaro, R
    Villa, E
    LUNG CANCER, 2004, 44 (02) : 231 - 239
  • [38] KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).
    Brahmer, Julie R.
    Kim, Edward S.
    Zhang, Jin
    Smith, Margaret Marie
    Rangwala, Reshma A.
    O'Brien, Mary E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study
    Mok, T.
    Wu, Y. -L.
    Sadowski, S.
    Zhang, J.
    Rangwala, R.
    de Lima Lopes, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [40] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
12345